M.E. SCOTT

M.B., B.S., F.R.A.C.P. PROVIDER NO. 235281J
ABN 68 704 564 763

[redacted]

[redacted]

[redacted]

MES:MS

17th February 2012
(Typed 17/2/12)

PBS Post Market
Dept of Health & Ageing
MDP 900
GPO Box 9848
CANBERRA ACT 2601

Dear Sir/Madam

Re: **Call for Submissions: Review of Anticoagulant Therapies in Atrial Fibrillation**

Of the five patients started on Pradaxa, four are still continuing.

The convenience to the patient and the marked decrease in the need for review as well as the decrease in secondary problems is quite apparent, relative to Warfarin, especially in the older patients i.e. I plan on seeing them six monthly and usually finished up seeing them within two to three months because of problems, but the review time has been increased to eight months. A marked increase in convenience to both the patient and myself.

With regard to Clopidogrel and Aspirin; I only use these in atrial fibrillation where there is no option as can certainly appear in the older age group, who are my clientele.

Yours faithfully

Malcolm E Scott

cc Boehringer Ingelheim P/L PO Box 1969 Macquarie Centre North Ryde NSW 2113

This letter and any accompanying documents are protected by the laws of Copyright and must not be reprinted, copied or otherwise disclosed in whole or in part, to any person without the written consent of Dr Malcolm E Scott.